Navigation Links
Chimerix to Present at Cowen and Company 31st Annual Health Care Conference
Date:3/1/2011

atients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The Open-Label Study builds on Chimerix's extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies.

CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases under Grant No. UO1-AI057233, in addition to new funding from the Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201100013C.

Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-week
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerixs Lead Antiviral CMX001
2. Chimerix to Present at the Citi 2011 Global Health Care Conference
3. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
4. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
5. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
6. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
7. Chimerix to Present at 9th Annual BIO Investor Forum
8. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
9. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
10. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
11. Chimerix to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and ... be able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of the ... steadfastly remains one of the most litigious industry ...
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... 16 BioVex Inc, a biotechnology,company developing clinical ... that the abstract describing the interim results,from its ... advanced metastatic,melanoma is now available at the American ... http://www.asco.org . A summary of the abstract,which describes ...
... Nektar,s Technology Enables First-Ever PEGylation of a Small Molecule with ... Demonstrated Therapeutic ... NKTR ) announced initial results today from a Phase ... activity in patients with refractory solid tumors. The study,also demonstrates ...
Cached Medicine Technology:BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5
(Date:4/17/2014)... 2014 EcoHealth Alliance, a nonprofit organization that focuses ... comprehensive review today examining the current state of knowledge ... calls for improved global surveillance strategies to combat the ... of Ebola in West Africa that has claimed the ... and Liberia. According to the World Health Organization ...
(Date:4/17/2014)... to ward off depression among retirees, particularly among those ... The Journals of Gerontology, Series B: Psychological ... " Internet Use and Depression Among Retired Older Adults ... authors report that Internet use reduced the probability of ... sample. , Late-life depression affects between 5 and ...
(Date:4/17/2014)... (17 April 2014) Population Council scientists and their partners ... stable, and can prevent the transmission of multiple sexually ... in animals: HIV, herpes simplex virus 2 (HSV-2), and ... first data that the gel is effective against multiple ... in the vagina against all three viruses of at ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
(Date:4/17/2014)... is less than 40 years away from a food ... governments, according to a top scientist at the U.S. ... human history, food production will be limited on a ... energy," said Dr. Fred Davies, senior science advisor for ... become as politically destabilizing by 2050 as energy issues ...
Breaking Medicine News(10 mins):Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Food shortages could be most critical world issue by mid-century 2
... a kind of disability. Researchers at Pope University, have found ... of aged people between 51 and 62.// ,Those ... cent more likely to report disabilities with respect to work ... greater risk. These were people who drank more than three ...
... aspirin because it thins the blood and prevents the ... widely used class of pain relievers known as nonsteroidal ... other aches and pains. The popular pain reliever ibuprofen ... study that sounds a warning for people who take ...
... are infected with HIV every year in the US, with ... of all U.S. patients with the AIDS virus have an ... to treat it. // Drug-resistant HIV had spread faster and ... normal lives were becoming increasingly limited in their usefulness. ...
... offer some protection against adult-onset diabetes.,An expert behind the ... benefit now by adding the spice to their food.// ... more prevalent than insulin-dependent diabetes, which normally begins earlier ... and insulin injections. It happens when cells in the ...
... is responsible for people who find it impossible to stay ... new treatments for jet lag//, insomnia and seasonal depression. ... cannot stay awake much after 8.30pm and who wake up ... advanced sleep-phase syndrome". This means the person's body clock is ...
... they have discovered the Holy Grail of bad smells ... effects of flatulence. American researchers believe the answer to ... that an object called a Toot Trapper, a cushion ... to almost unnoticeable levels. ,The scientists from ...
Cached Medicine News:Health News:Sniff out flatulence, 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: